Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of UB-612 COVID-19 Vaccine in Adolescents and Adults
NCT04773067Phase 2Terminated
- Sponsor
- United Biomedical, Inc.
- Start
- Jan 2021
- Primary completion
- Mar 2022
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing UB-612 with Placebo (2 arms). Primary endpoints: Geometric Mean Titer (GMT) of SARS-CoV-2 Neutralizing Antibody at Day 57, Seroconversion Rate (SCR) of SARS-CoV-2 Neutralizing Antibody at Day 57 and 3 more. Started Jan 2021; status: terminated.
02
Drugs
UB-612
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04773067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773067.